Definition

An orally bioavailable and irreversible covalent inhibitor of Bruton’s tyrosine kinase (BTK), with potential antineoplastic activity. Upon oral administration, BTK inhibitor ABBV-992 targets, binds to and inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies. It plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival.